Positive expression of GSK3β is associated with poor prognosis for NSCLC.

<p>(<b>A</b>) In the entire group, patients with positive GSK3β expression had shorter survival times, <i>P</i> = 0.006. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091231#pone-0091231-g002" target="_blank">Figure 2B-D</a> shows the survival analysis for the subgroups. (<b>B</b>) In the lower differentiation subgroup, patients with positive GSK3β expression had significantly shorter survival times, <i>P</i> = 0.013. (<b>C</b>) In the T1+T2 subgroup, patients with positive GSK3β expression had significantly shorter survival times, <i>P</i> = 0.003. (<b>D</b>) In the N0+N1 subgroup, patients with positive GSK3β expression had significantly shorter survival times, <i>P</i> = 0.010. (E) Patients in the M0 subgroup with positive GSK3β expression had significantly shorter survival times, <i>P</i> = 0.008. Kaplan-Meier curves for the investigated proteins were used to compare the positive (<i>dashed lines</i>) and negative phenotypes (<i>solid lines</i>)<b>.</b>